Continue to Site

Drug Discovery and Development

Terns Pharmaceuticals adds former AstraZeneca CMO to board 

By |

Terns PharmaceuticalsThe biopharma Terns Pharmaceuticals (NSDQ:TERN) has appointed Dr. ​​Ann E. Taylor to its board of directors. 

Taylor, who served as AstraZeneca‘s chief medical officer from April 2019 to August 2021, has more than 35 years of experience in drug development. Other notable companies she has worked for include Pfizer, Novartis and AstraZeneca subsidiary MedImmune. 

Ann Taylor

Dr. ​​Ann E. Taylor

Dr. Taylor currently serves on the board of directors of Unlearn.AI, a company focused on accelerating clinical trials with artificial intelligence. 

She has authored and co-authored 48 peer-reviewed papers, 27 book chapters and reviews and served on the editorial board of the Journal of Clinical Endocrinology and Metabolism.

Foster City, California–based Terns is focused on developing therapies for nonalcoholic steatohepatitis (NASH), which involves liver inflammation and potentially scarring (cirrhosis). “NASH remains an area of significant unmet need and I believe Terns’ approach, which seeks to combine best-in-class molecules with clinically validated mechanisms in NASH, will play a significant part in the treatment of NASH patients,” said Taylor, in a statement.

Earlier this month, Terns announced it had completed patient enrollment of Part 1 of its AVIATION Trial, a Phase 1b study investigating TERN-201 in NASH. The drug is a highly selective inhibitor of vascular adhesion protein-1 (VAP-1).  

Filed Under: Hepatology
Tagged With: , ,
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development